XpresTest, a biosecurity company, was awarded nearly $40 million in federal contracts for screening diseases like Ebola, following an investment from a firm linked to President Trump's sons. The contracts include screening at U.S. airports and responding to outbreaks in the Democratic Republic of Congo, raising concerns due to the company's lack of experience in such international operations. Critics question the decision to award contracts to a relatively inexperienced firm.
Key facts
- XpresTest received nearly $40 million in federal contracts.
- The contracts involve screening for Ebola at U.S. airports and in the Democratic Republic of Congo.
- XpresTest has no prior experience with Ebola or international biosecurity.
- The Trump sons are described as passive investors in XWELL.
- The contracts were awarded through a competitive bidding process.
A short AI summary in our own words. The reporting belongs to propublica.org; we don't reproduce it.